SSRIs and Learning-Associated Neural Plasticity

Phase 4, randomised, double-blind trial of Escitalopram oxalate oral solution in major depressive disorder (MDD) and anxiety disorder (2 arms), sponsored by Medical University of Vienna. Primary endpoints: Gray matter volume at 21 days and Mean diffusivity at 21 days. Status: unknown.